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Abstract
Summary Diagnosis and treatment of osteoporosis in
hospitals is poor. We compared patient outcomes before
and after implementation of a clinical protocol for low-
trauma fractures. Patients in the pathway were more likely
to receive information about osteoporosis or osteoporosis
medications. Therefore our clinical pathway is effective in
improving osteoporosis information and treatment.
Introduction Effective therapies for reducing fracture risk are
available, yet under-utilised in hospital settings. We aimed to
increase rates of initiation of osteoporosis investigations,
pharmacological treatment, treatment continuation, and fol-
low-up general practitioner (GP) visits.
Methods Comparison of patient outcomes before and after
implementation of a clinical pathway in patients admitted
for low-trauma fractures to the Department of Orthopaedics
and Trauma at The Queen Elizabeth Hospital, Adelaide.
Results Patients enrolled in the osteoporosis clinical path-
way (n=28) were more likely than patients receiving usual
care (n=28) to have received information about (54% vs.
29%; p<0.05), or a prescription for osteoporosis medica-
tion (53% vs. 25%, p<0.05). Differences in proportions of
patients visiting their GP post fracture and in osteoporosis
investigations suggested or undertaken were not significant.
At the later audit, the high proportion of patients receiving
information about osteoporosis medication had been main-
tained (51%). Prescription of osteoporosis medications
increased to 83% (p<0.01), and more patients saw their
GP post fracture (87%; p<0.01). High rates of medication
adherence were reported in patients in all groups receiving
prescriptions.
Conclusion A clinical pathway for improving hospital
management of osteoporosis is effective in improving
education about, prescription for, and uptake of osteoporosis
medications.
Keywords Osteoporosis . Clinical protocols .
Bone density . Fractures
Introduction
Osteoporosis is a common, yet under-diagnosed and under-
treated form of musculoskeletal disease [1] which is
associated with bone fractures. Approximately one third
of men and half of women aged over 60 will sustain a
fracture in their lifetime [2]. Experiencing a fragility
fracture is associated with significant rates of morbidity
and mortality, particularly in the case of hip fractures [3, 4],
and places the individual at increased risk of further
fractures [5–7]. Osteoporosis is expensive, costing Austra-
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lian taxpayers an estimated A$7.4 billion per annum, with
over 25,000 healthy lives lost in the financial year 2000–01
[8]. Despite evidence that further fractures may be
prevented through patient education and initiation of
pharmacological treatment [9–11], self-reported prevalence
of osteoporosis is low [12], and many patients who sustain
a fracture do not receive any diagnosis, treatment or
information regarding osteoporosis [13, 14]; and patients
leave hospital with their fracture treated but with osteopo-
rosis uninvestigated, undiagnosed and untreated [13–19].
Therefore, targeting patients who sustain fractures to
receive assessment and treatment may reduce refracture
rates and subsequently the personal, social and economic
burden of osteoporosis.
The study had the following objectives:
– to evaluate the efficacy of an osteoporosis clinical
pathway designed to increase rates of follow-up,
investigation and treatment for osteoporosis adminis-
tered in a hospital setting,
– to determine the rates of follow-up by a general
practitioner (GP) post-fracture, and subsequent rates
of investigation and treatment for osteoporosis,
– to examine the prevalence and source of patient
education regarding osteoporosis and osteoporosis-
related services,
– to investigate long-term pharmacological osteoporosis
prophylaxis use in patients enrolled in the clinical
pathway,
– to determine re-fracture rates in these patients,
– to investigate general practitioners compliance with
suggested investigations and treatment plans for these
patients post-discharge from acute care.
Materials and methods
Phase 1: Comparison of patients before and after pathway
introduction
Setting and participants
Participants were patients, aged ≥45 years who had been
admitted to the Department of Orthopaedics and Trauma at
The Queen Elizabeth Hospital (TQEH), South Australia,
between 1 May 2003 and 31 January 2004 for treatment of
a fracture sustained with a minimal degree of trauma or
subsequent to a fall from standing height or less. The first
48 patients who were admitted after 1 May 2003 received
standard care under existing protocols and were treated as
the control group, while the ‘pathway group’ were the first
49 patients enrolled in the osteoporosis clinical pathway
after July 2003. Patients were excluded (N=7) if they had
insufficient contact details or were deceased when matched
to mortality data. Next of kin were approached if patients
had memory loss or dementia. Participants provided written
informed consent in accordance with the Declaration of
Helsinki (1996). The study was approved by the North
Western Adelaide Health Service Ethics of Human Re-
search Committee. Fifty-six patients or next-of-kin (62%,
56/90) consented to participate and completed a question-
naire. The final sample included 28 subjects in each of the
control and pathway groups.
Intervention
Patients meeting inclusion criteria were identified by the
clinical pharmacist from computerised hospital lists and
case notes. Treatment consisted of oral triple therapy of a
bisphosphonate (risedronate 35 mg weekly), calcium
supplement (600 mg twice daily) and a Vitamin D
supplement (ergocalciferol 1000 units daily). Contraindi-
cations to risedronate were gastric ulceration, previous
intolerance to a bisphosphonate, or inability to sit upright
for 30 minutes after administration. The pharmacist
recommended prescription of triple pack therapy by junior
medical officers both during admission and on discharge
with backup and reinforcement by the orthopaedic
physician.
Patients commencing therapy received individual
counselling from the clinical pharmacist and were provided
with a standard osteoporosis pack. Interpreters were used,
and next of kin were contacted in patients with dementia.
Each pack contained patient information about osteoporosis
and the drugs prescribed, a letter to the general practitioner
(GP), an information leaflet for a physiotherapy self-
management course, a list of local community falls
prevention services, and support products for risedronate.
This was presented in a bright orange bag and labelled
“Osteoporosis Pack”. Patients were offered the opportunity
to enrol in the Aventis ACTNOW support programme.
The letter to the patients’ GP stated that the patient had
been identified as having an osteoporotic fracture and had
been provided with an osteoporosis pack. Also included
were the date of the X-ray that confirmed the fracture,
medications prescribed and suggestions as to the investiga-
tion of secondary causes of osteoporosis. It was clearly
stated that although the patient had been started on
refracture prevention therapy NO investigations of osteo-
porosis or secondary causes had been undertaken.
Procedure
Participants completed follow-up questionnaires by home
interview or mail 6–12 months following hospital admis-
sion for the fracture (mean 44±13 weeks). Information
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collected in the questionnaire included the following:
demographic information, osteoporosis lifestyle factors,
falls and fracture history, family history of fractures or
osteoporosis, treatments taken before or initiated following
the fracture, osteoporosis-related investigations suggested
or undertaken (e.g., bone density test by DXA (dual
emission X-ray absorptiometry) serum calcium and vitamin
D), follow-up visits to a GP, and whether any information
about osteoporosis or osteoporosis-related services had
been provided to the patient, as well as the source of the
information.
Phase 2: Evaluation of the osteoporosis clinical pathway
and General Practitioner feedback
This phase incorporated patients enrolled in the osteoporo-
sis care pathway from February–October 2004. Participants
or their proxy (next of kin or nursing home staff member)
were interviewed by telephone. Information collected was
identical to that collected in phase 1 of the study.
In addition to collecting patient information, a single
page questionnaire was sent to all GP’s in the catchment
area of TQEH by the Western Adelaide Division of General
Practice. This requested information about whether indi-
vidual patients had been seen by the GP post-discharge, and
whether investigations and prophylactic medications sug-
gested under the protocol had been arranged.
Statistical analyses
Chi-square and student t-tests were used to examine sample
characteristics. Significance levels of 10% were used in
phase 1 due to the small sample size. Conventional
significance levels of 5% were used in phase 2. Analyses
were conducted using SPSS version 12.0.1 (phase 1) and
SPSS version 13.0 (phase 2).
Results
Patient characteristics
Table 1 shows that in phase 1 of the study patients in the
pathway group were significantly older than the control
group, less likely to have completed high school, more
likely to have had their questionnaire completed by next-of-
kin, and, by study design, had shorter time to interview.
There were no significant differences between the two
groups in regard to gender, place of residence or osteopo-
rosis risk factors. Table 1 also shows that patients in phase
2 of the study were similar to the control group in phase 1
in relation to gender, place of residence and survey
respondent.
The most common site of fracture was the hip (See
Fig. 1). There were no significant differences in fracture
types between pathway and control patients (phase 1) or
between patients in phase 1 and phase 2. In phase 2 of the
study, two participants presented with a more than one
fracture at time of admission.
Osteoporosis investigations
Table 2 shows that in phase 1 of the study there were no
significant differences between patients enrolled in the
pathway and control patients in relation to recommenda-
tions for or initiation of osteoporosis investigations.
Osteoporosis medication
Table 3 shows that in phase 1 of the study significantly
more patients enrolled in the care pathway recalled
receiving information about medication that could improve
bone density or may help in preventing future fractures.
Table 3 also shows that this level of recall was maintained
in phase 2 of the study. Information about osteoporosis




a statistically significant differ-
ence between phase 1 usual
care and phase 1 pathway
b statistically significant differ-
ence between phase 1 usual
care and phase 2 pathway
Phase 1 Usual Care Phase 1 Pathway Phase 2 Pathway
n=28 n=28 n=65
Demographics
Age, mean±SD (yrs)a** 71.3±13.7 79.2±8.4 76.17
Female (%)a** 71.4 78.6 70.8
Did not complete high school (%)a* 57.1 78.6 Not collected
Resident of nursing home (%) 14.3 32.1 15.4
Time to interview, mean ± SD (wks) 55.3±4.4 32.7±7.1 Not collected
Next-of-kin as respondent (%)a** 10.7 39.3 20.0
Osteoporosis risk factors
Current smoking (%)b** 25.0 14.3 4.6
Previous adult fracture (%) 53.6 42.9 33.8
Family history of fracture (%) 35.7 17.9 32.3
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however, information was also provided by hospital
pharmacy staff, an orthopaedic surgeon or from other
sources. Patients in the pathway group in phase 1 were
more likely than controls to have had osteoporosis
medication (bisphosphonate, calcium, vitamin D or hor-
mone replacement therapy) prescribed but this difference
was not statistically significant. The majority of patients for
whom osteoporosis medication was prescribed, commenced
and continued prescribed medications; these numbers were
not significantly different between pathway and control
groups. The majority of patients in phase 2 were also
prescribed osteoporosis medication; most of these patients
commenced and continued the medication. Reasons for
ceasing medication included the patient not understanding
why the medication was needed, the patient reporting
experiencing side effects, being unwilling to take the
medication or not having a prescription renewed by a GP.
General practitioner follow-up
The majority of patients consulted a GP following their
fracture (See Table 4). Most of these consultations occurred
within one month of the patient sustaining the fracture.
There was no significant difference between the pathway
and usual care groups in to the proportion who visited a GP
for follow-up, although patients in phase 2 were more likely
to have seen a GP than patients in phase 1. Reasons
provided for not seeing a GP post fracture included: patient
being discharged to a rehabilitation centre (35%), patient
was a resident of a nursing home (15%) and patient belief
that they did not need to visit a GP because the fracture had
been “fixed” (25%)
GP responses to emailed questionnaire
No responses to the emailed questionnaire were received
from GPs in the hospital catchment area.
Discussion
The results of this study demonstrate that a clinical pathway
administered in a hospital setting is an effective means of
increasing rates of treatment and follow-up for osteoporosis
in this patient group. The increase in the prescription of
osteoporosis medications following pathway introduction
seen in phase 1 of the current study is similar to results of
an audit of a fracture protocol in Tasmania, Australia [20].
However, we have also demonstrated that this increase in
prescription of osteoporosis medications is sustained over
time, and that initiating pharmacological treatment in a
hospital environment appears to influence the rate that
patients fill their scripts and continue to take the medication
after discharge. To maintain this level of adherence also
requires that the medical practitioners who see the patients
after discharge from hospital continue to prescribe these
medications. We found that individuals who were enrolled
in the osteoporosis clinical pathway were no more likely
than controls to receive osteoporosis investigations (e.g.,
DXA, serum calcium and Vitamin D), but were signifi-
cantly more likely to have received information about
pharmaceutical interventions, and more likely to have
actually been prescribed pharmacological osteoporosis
prophylaxis. Regardless of whether patients were enrolled
in the pathway, adherence to prescribed medications was
still high at the follow-up audit.
The results of this study provide support for those of
Majumdar et al. [15] who found that treatment delivered via
an osteoporosis pathway was associated with an increase in
the rates of BMD testing and prescription of osteoporosis
treatment. The results also support those of Sidwell et al.
[16], who found that there was improvement in the
management and treatment of osteoporosis in patients
enrolled in a clinical pathway.
The inclusion of patients with dementia through proxy
interviewing is a strength of this study. This group is at
significant risk of falls and fractures [21], yet are often
excluded from research due to the difficulties associated
with obtaining consent and collecting information. Face-to-
face home interviews in phase 1 of the study assisted in a








Investigation suggested 32.1 39.3 29.2
Investigation initiated 32.1 35.7 26.1
DXAa suggested 25.0 28.6 27.7
DXA conducted 25.0 21.4 29.2
Vitamin D/calcium test suggested 17.9 35.7 29.2
Vitamin D/calcium checked 14.3 28.6 29.2
a DXA=dual emission X-ray absorptiometry







Other Phase 1 Usual care
Phase 1 Pathway
Phase 2 (Pathway)
Fig. 1 Site of bone fracture
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reasonable response rate (62%) and ensured that patients
with hearing difficulties or those too frail to travel were
able to participate in the study.
However the study does have several limitations. Due to
time and funding restrictions, the sample size in phase 1
proved insufficient to achieve statistically significant differ-
ences between groups for some parameters recorded. The
retrospective study design relied on participant recall and it
is therefore difficult to ascertain the accuracy with which
participants may have recalled events that had occurred
some time previously. phase 1 participants in both the
control and pathway groups anecdotally reported that they
were distressed and confused whilst in hospital and had
difficulty in recalling any information that they received
during their admission. It is also possible that patient’s next-
of-kin or nursing home staff were unaware of the osteoporosis
information provided to fragility fracture patients whilst in
hospital. Validity of the study could be improved by
comparing participant responses from hospital, GP, or
pharmacy records.
The Queen Elizabeth Hospital is located in a low socio-
economic area within Adelaide [22]; therefore these
findings may be generalisable to hospital populations with
similar socio-economic status and education levels but not
necessarily to the wider South Australian population.
Despite efforts to examine the contribution of GPs to the
success of the osteoporosis clinical pathway, no responses
were received for this section of the study.
In conclusion, despite the number of studies advocating
the need for greater efforts in diagnosing and treating
osteoporosis in fragility fracture patients, there have not
been efficient clinical pathways developed in South
Australia to assist in the provision of appropriate investi-
gation and treatment. Evidence suggests that clinical path-
Table 3 Osteoporosis treatment, medications and services
Phase 1 Usual care Phase 1 Pathway Phase 2 Pathway
n=28 n=28 n=65
n % n % n %
Received information about osteoporosis medicationd**,e** 8 28.6 15 53.6 33 50.8
Source of information about osteoporosis medicationa
General practitionerc 9 39.0 12 36.4
Hospital pharmacy staff 6 26.0 6 18.1
Orthopaedic surgeon 3 13.0 6 18.1
Other sources 3 13.0 2 6.1
Could not remember 2 9.0 7 21.3
Total 23 100.0 33 100.0
Any osteoporosis medication prescribedd**,e***,f*** 7 25.0 15 53.6 54 83.1
Medication commencedb,d**, 7 100.0 13 86.7 48 88.9
Medication continuedb 6 85.7 10 76.9 46 95.8
a Pooled data from pathway and control groups in phase 1
b Denominator is N in column immediately above
c Fisher’s exact test used due to small cell sizes
**p≤0.05, ***p≤0.01.
d statistically significant difference between phase 1 usual care and phase 1 pathway
e statistically significant difference between phase 1 usual care and phase 2 pathway
f statistically significant difference between phase 1 pathway and phase 2 pathway
Table 4 General practitioner
follow-up
a Pooled data from pathway
and control groups in phase 1
***p≤0.01.
b statistically significant differ-
ence between phase 1 pathway
and phase 2 pathway
c Not multiple response
Phase 1 Usual Care Phase 1 Pathway Phase 2 Pathway
n=28 n=28 n=65
n % n % n %
Saw GP following fractureb*** 20 71.4 16 57.1 57 87.6
Reasons for not seeing GPa,c
Discharge to rehab hospital 7 28.6
Nursing home resident 3 19.0
Fracture fixed 5 52.4
Other 5 28.6
Total 20 100.0
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ways may be an effective means with which these issues
can be addressed; however, there is still a significant
problem with failure to adequately follow up patients to
ensure that recommendations for investigation and treat-
ment are heeded.
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